Saturday, November 18, 2023
Owl Therapeutics, a subsidiary of Gryphon Bio, has recently entered into a global licensing and collaboration agreement with Abliva AB based in Lund, Sweden. The collaboration aims to advance Abliva's NeuroSTAT® (OWL-1410) for the prevention and treatment of moderate to severe traumatic brain injury (TBI).
Traumatic brain injury poses a significant public health challenge, affecting millions annually due to head trauma from various causes such as accidents, falls, sports-related incidents, and military combat. This injury disrupts normal brain functioning, leading to cognitive, physical, and emotional symptoms. The agreement grants Owl Therapeutics a global license for the development, manufacturing, and commercialization of NeuroSTAT®.
Owl Therapeutics and CEO of Gryphon Bio, expressed enthusiasm for the partnership with Abliva, emphasizing their joint commitment to advancing NeuroSTAT®. The collaboration leverages the scientific, clinical, and business expertise of both entities to potentially revolutionize treatment for TBI patients.
Abliva will contribute to the operational and strategic aspects of the program through a steering committee. Owl Therapeutics will take the lead in the clinical development and commercialization of NeuroSTAT®, with Abliva eligible for royalties upon commercialization.
Owl Therapeutics highlighted the benefits of gaining access to an innovative asset with orphan drug designation in Europe and the U.S., as well as Fast Track designation for clinical development and review in the U.S.
NeuroSTAT® has demonstrated promise in advanced experimental TBI models, replicating human disease. The collaboration aims to rapidly advance this potential treatment, with the endorsement of the scientific community, including TBI researcher Todd Kilbaugh.
Owl Therapeutics, emphasized the agreement as a strong endorsement of Owl's TBI expertise. NeuroSTAT® has shown promise in reducing blood biomarkers of neuronal injury in both experimental TBI models and clinical studies.
TBI imposes a significant burden on healthcare systems and society, incurring substantial expenses. Addressing this health issue requires ongoing research focused on prevention, diagnosis, and treatment. The collaboration between Owl Therapeutics and Abliva represents a concerted effort to address the complexities of TBI and improve patient outcomes.